Next generation protein multiplexing
Inanovate, Inc, North Carolina, United States
Inanovate has developed a new category of protein multiplexing technology called Longitudinal Assay Screening (LAS). The longitudinal process of LAS can be viewed as running multiple sequential fluorescent assays in an automated micro-fluidic environment, generating information on binding kinetics of biomarkers in real-time; delivering a transformative solution to protein multiplexing.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 5
FIGURES OF MERIT
Value Proposition: Inanovate's advantage is predicted on a patented method for protein multiplexing, called LAS. LAS enables users to accurately measure virtually any combination of proteins from one sample, in one test. This directly addresses critical needs for improved accuracy and improved clinical relevance of protein based diagnostic tests.
Organization Type: Mid-stage Startup (A or B)
Showcase Booth #: 719
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: The NCI has to date helped fund the development of Inanovate’s Bio-ID platform through Phase I and Phase II SBIR grant. Committing a total of $1.75 million towards its development and validation. Inanovate successfully completed the Phase II SBIR program in September 2013, and the NCI have since invited Inanovate onto their Phase II Bridge program – an exclusive program that will match private financing on a dollar for dollar basis up to $3 million of NCI funding support.
Primary Sources of Funding: Angel, Friends, Family, Federal Grant
Looking for: Both Funding and Development Partners